Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma

Marcel P DeVetten, Parameswaran N. Hari, Jeanette Carreras, Brent R. Logan, Koen van Besien, Christopher N. Bredeson, César O. Freytes, Robert Peter Gale, John Gibson, Sergio A. Giralt, Steven C. Goldstein, Vikas Gupta, David I. Marks, Richard T. Maziarz, Julie Marie Vose, Hillard M. Lazarus, Paolo Anderlini

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Myeloablative allogeneic hematopoietic cell transplantation (HCT) may cure patients with relapsed or refractory Hodgkin lymphoma (HL), but is associated with a high treatment-related mortality (TRM). Reduced-intensity and nonmyeloablative (RIC/NST) conditioning regimens aim to lower TRM. We analyzed the outcomes of 143 patients undergoing unrelated donor RIC/NST HCT for relapsed and refractory HL between 1999 and 2004 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Patients were heavily pretreated, including autologous HCT in 89%. With a median follow-up of 25 months, the probability of TRM at day 100 and 2 years was 15% (95% confidence interval [CI] 10%-21%) and 33% (95% CI 25%-41%), respectively. The probabilities of progression free survival (PFS) and overall survival (OS) were 30% and 56% at 1 year and 20% and 37% at 2 years. The presence of extranodal disease and the Karnofsky Performance Scale (KPS) <90 were significant risk factors for TRM, PFS, and OS, whereas chemosensitivity at transplantation was not. Dose intensity of the conditioning regimen (RIC versus NST) did not impact outcomes. Unrelated donor HCT with RIC/NST can salvage some patients with relapsed/refractory HL, but relapse remains a common reason for treatment failure. Clinical studies should be aimed at reducing the incidence of acute graft-versus-host disease (GVHD) and relapse.

Original languageEnglish (US)
Pages (from-to)109-117
Number of pages9
JournalBiology of Blood and Marrow Transplantation
Volume15
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Unrelated Donors
Hematopoietic Stem Cell Transplantation
Cell Transplantation
Hodgkin Disease
Mortality
Disease-Free Survival
Confidence Intervals
Karnofsky Performance Status
Recurrence
Survival
Graft vs Host Disease
Therapeutics
Treatment Failure
Transplantation
Bone Marrow
Transplants
Incidence
Research

Keywords

  • Allogeneic transplantation
  • Hodgkin lymphoma
  • Unrelated

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. / DeVetten, Marcel P; Hari, Parameswaran N.; Carreras, Jeanette; Logan, Brent R.; van Besien, Koen; Bredeson, Christopher N.; Freytes, César O.; Gale, Robert Peter; Gibson, John; Giralt, Sergio A.; Goldstein, Steven C.; Gupta, Vikas; Marks, David I.; Maziarz, Richard T.; Vose, Julie Marie; Lazarus, Hillard M.; Anderlini, Paolo.

In: Biology of Blood and Marrow Transplantation, Vol. 15, No. 1, 01.01.2009, p. 109-117.

Research output: Contribution to journalArticle

DeVetten, MP, Hari, PN, Carreras, J, Logan, BR, van Besien, K, Bredeson, CN, Freytes, CO, Gale, RP, Gibson, J, Giralt, SA, Goldstein, SC, Gupta, V, Marks, DI, Maziarz, RT, Vose, JM, Lazarus, HM & Anderlini, P 2009, 'Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma', Biology of Blood and Marrow Transplantation, vol. 15, no. 1, pp. 109-117. https://doi.org/10.1016/j.bbmt.2008.11.011
DeVetten, Marcel P ; Hari, Parameswaran N. ; Carreras, Jeanette ; Logan, Brent R. ; van Besien, Koen ; Bredeson, Christopher N. ; Freytes, César O. ; Gale, Robert Peter ; Gibson, John ; Giralt, Sergio A. ; Goldstein, Steven C. ; Gupta, Vikas ; Marks, David I. ; Maziarz, Richard T. ; Vose, Julie Marie ; Lazarus, Hillard M. ; Anderlini, Paolo. / Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. In: Biology of Blood and Marrow Transplantation. 2009 ; Vol. 15, No. 1. pp. 109-117.
@article{52ec7cfb49f649fba495a431d7f6359f,
title = "Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma",
abstract = "Myeloablative allogeneic hematopoietic cell transplantation (HCT) may cure patients with relapsed or refractory Hodgkin lymphoma (HL), but is associated with a high treatment-related mortality (TRM). Reduced-intensity and nonmyeloablative (RIC/NST) conditioning regimens aim to lower TRM. We analyzed the outcomes of 143 patients undergoing unrelated donor RIC/NST HCT for relapsed and refractory HL between 1999 and 2004 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Patients were heavily pretreated, including autologous HCT in 89{\%}. With a median follow-up of 25 months, the probability of TRM at day 100 and 2 years was 15{\%} (95{\%} confidence interval [CI] 10{\%}-21{\%}) and 33{\%} (95{\%} CI 25{\%}-41{\%}), respectively. The probabilities of progression free survival (PFS) and overall survival (OS) were 30{\%} and 56{\%} at 1 year and 20{\%} and 37{\%} at 2 years. The presence of extranodal disease and the Karnofsky Performance Scale (KPS) <90 were significant risk factors for TRM, PFS, and OS, whereas chemosensitivity at transplantation was not. Dose intensity of the conditioning regimen (RIC versus NST) did not impact outcomes. Unrelated donor HCT with RIC/NST can salvage some patients with relapsed/refractory HL, but relapse remains a common reason for treatment failure. Clinical studies should be aimed at reducing the incidence of acute graft-versus-host disease (GVHD) and relapse.",
keywords = "Allogeneic transplantation, Hodgkin lymphoma, Unrelated",
author = "DeVetten, {Marcel P} and Hari, {Parameswaran N.} and Jeanette Carreras and Logan, {Brent R.} and {van Besien}, Koen and Bredeson, {Christopher N.} and Freytes, {C{\'e}sar O.} and Gale, {Robert Peter} and John Gibson and Giralt, {Sergio A.} and Goldstein, {Steven C.} and Vikas Gupta and Marks, {David I.} and Maziarz, {Richard T.} and Vose, {Julie Marie} and Lazarus, {Hillard M.} and Paolo Anderlini",
year = "2009",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2008.11.011",
language = "English (US)",
volume = "15",
pages = "109--117",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma

AU - DeVetten, Marcel P

AU - Hari, Parameswaran N.

AU - Carreras, Jeanette

AU - Logan, Brent R.

AU - van Besien, Koen

AU - Bredeson, Christopher N.

AU - Freytes, César O.

AU - Gale, Robert Peter

AU - Gibson, John

AU - Giralt, Sergio A.

AU - Goldstein, Steven C.

AU - Gupta, Vikas

AU - Marks, David I.

AU - Maziarz, Richard T.

AU - Vose, Julie Marie

AU - Lazarus, Hillard M.

AU - Anderlini, Paolo

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Myeloablative allogeneic hematopoietic cell transplantation (HCT) may cure patients with relapsed or refractory Hodgkin lymphoma (HL), but is associated with a high treatment-related mortality (TRM). Reduced-intensity and nonmyeloablative (RIC/NST) conditioning regimens aim to lower TRM. We analyzed the outcomes of 143 patients undergoing unrelated donor RIC/NST HCT for relapsed and refractory HL between 1999 and 2004 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Patients were heavily pretreated, including autologous HCT in 89%. With a median follow-up of 25 months, the probability of TRM at day 100 and 2 years was 15% (95% confidence interval [CI] 10%-21%) and 33% (95% CI 25%-41%), respectively. The probabilities of progression free survival (PFS) and overall survival (OS) were 30% and 56% at 1 year and 20% and 37% at 2 years. The presence of extranodal disease and the Karnofsky Performance Scale (KPS) <90 were significant risk factors for TRM, PFS, and OS, whereas chemosensitivity at transplantation was not. Dose intensity of the conditioning regimen (RIC versus NST) did not impact outcomes. Unrelated donor HCT with RIC/NST can salvage some patients with relapsed/refractory HL, but relapse remains a common reason for treatment failure. Clinical studies should be aimed at reducing the incidence of acute graft-versus-host disease (GVHD) and relapse.

AB - Myeloablative allogeneic hematopoietic cell transplantation (HCT) may cure patients with relapsed or refractory Hodgkin lymphoma (HL), but is associated with a high treatment-related mortality (TRM). Reduced-intensity and nonmyeloablative (RIC/NST) conditioning regimens aim to lower TRM. We analyzed the outcomes of 143 patients undergoing unrelated donor RIC/NST HCT for relapsed and refractory HL between 1999 and 2004 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Patients were heavily pretreated, including autologous HCT in 89%. With a median follow-up of 25 months, the probability of TRM at day 100 and 2 years was 15% (95% confidence interval [CI] 10%-21%) and 33% (95% CI 25%-41%), respectively. The probabilities of progression free survival (PFS) and overall survival (OS) were 30% and 56% at 1 year and 20% and 37% at 2 years. The presence of extranodal disease and the Karnofsky Performance Scale (KPS) <90 were significant risk factors for TRM, PFS, and OS, whereas chemosensitivity at transplantation was not. Dose intensity of the conditioning regimen (RIC versus NST) did not impact outcomes. Unrelated donor HCT with RIC/NST can salvage some patients with relapsed/refractory HL, but relapse remains a common reason for treatment failure. Clinical studies should be aimed at reducing the incidence of acute graft-versus-host disease (GVHD) and relapse.

KW - Allogeneic transplantation

KW - Hodgkin lymphoma

KW - Unrelated

UR - http://www.scopus.com/inward/record.url?scp=58149197557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149197557&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2008.11.011

DO - 10.1016/j.bbmt.2008.11.011

M3 - Article

C2 - 19135949

AN - SCOPUS:58149197557

VL - 15

SP - 109

EP - 117

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 1

ER -